Published in J Natl Cancer Inst on July 04, 2001
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med (2003) 3.11
Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst (2014) 2.37
A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics (2008) 2.34
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol (2002) 2.09
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 1.97
Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol (2011) 1.97
Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics (2006) 1.93
Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol (2013) 1.84
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci (2005) 1.73
Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71
Prognostic molecular markers in early breast cancer. Breast Cancer Res (2004) 1.56
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res (2008) 1.48
Merging microarray data from separate breast cancer studies provides a robust prognostic test. BMC Bioinformatics (2008) 1.48
Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ (2004) 1.46
The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer (2009) 1.34
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol (2006) 1.21
Molecular profiling of breast cancer: clinical implications. Br J Cancer (2004) 1.19
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer (2007) 1.19
Involving patients in cardiovascular risk management with nurse-led clinics: a cluster randomized controlled trial. CMAJ (2009) 1.16
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res (2008) 1.11
Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A (2011) 1.09
Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem (2009) 1.09
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr (2010) 1.06
Pathway-based classification of cancer subtypes. Biol Direct (2012) 1.05
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics (2004) 1.05
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res (2009) 1.04
Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Am J Clin Oncol (2008) 1.03
Search for the smallest random forest. Stat Interface (2009) 1.00
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One (2013) 0.98
Active roles of tumor stroma in breast cancer metastasis. Int J Breast Cancer (2012) 0.98
Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol (2016) 0.98
Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn (2009) 0.97
Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg (2003) 0.97
99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI. PLoS One (2014) 0.97
Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. Br J Cancer (2008) 0.97
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract (2013) 0.96
Gene expression profiling of breast cancer survivability by pooled cDNA microarray analysis using logistic regression, artificial neural networks and decision trees. BMC Bioinformatics (2013) 0.96
Oncology care in rural northern new England. J Oncol Pract (2010) 0.96
Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg (2003) 0.95
Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: is there a role for radiation therapy? Radiat Oncol (2011) 0.95
Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health (2015) 0.92
Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process. Cancer (2009) 0.91
Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol (2013) 0.90
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res (2010) 0.89
A prognostic index for operable, node-negative breast cancer. Br J Cancer (2004) 0.89
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol (2016) 0.87
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer (2009) 0.87
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res (2013) 0.86
Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients. Breast Cancer Res Treat (2014) 0.86
Derivation of cancer diagnostic and prognostic signatures from gene expression data. Bioanalysis (2010) 0.86
Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment. Med Sci Monit (2012) 0.86
Community-based assessment of adjuvant hormone therapy in women with breast cancer, 1991-1997. Breast J (2004) 0.86
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer (2004) 0.85
Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype? Indian J Surg Oncol (2011) 0.84
Predictors and outcomes of surgeons' referral of older breast cancer patients to medical oncologists. Cancer (2005) 0.84
Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy - a retrospective analysis. BMC Cancer (2008) 0.84
A systems approach to clinical oncology: focus on breast cancer. Proteome Sci (2006) 0.84
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol (2015) 0.83
Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys (2007) 0.83
Differential gene expression in primary breast tumors associated with lymph node metastasis. Int J Breast Cancer (2011) 0.83
Should Postmastectomy Radiotherapy to the Chest Wall and Regional Lymph Nodes Be Standard for Patients with 1-3 Positive Lymph Nodes? Breast Care (Basel) (2011) 0.83
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One (2014) 0.83
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer (2005) 0.82
Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J Mol Diagn (2007) 0.82
Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer (2009) 0.82
A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients. Radiat Res (2009) 0.82
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer (2002) 0.82
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. EPMA J (2010) 0.81
Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract (2011) 0.81
Disparities in the use of radiation therapy in patients with local-regionally advanced breast cancer. Int J Radiat Oncol Biol Phys (2010) 0.81
Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia. Health Serv Res (2014) 0.81
Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. Oncogenesis (2014) 0.81
STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers. Oncotarget (2016) 0.80
Spectrum of very early breast cancer in a setting without organised screening. Br J Cancer (2014) 0.80
Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. J Transl Med (2010) 0.80
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat (2011) 0.80
Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles. Genetics (2016) 0.79
Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date. Br J Radiol (2015) 0.79
Perspectives on Breast Cancer Management: Tailoring Treatment to the Individual Patient. Breast Care (Basel) (2008) 0.79
Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. J Vis Exp (2011) 0.78
Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay. Chem Sci (2015) 0.78
Second malignancies after breast cancer: The impact of adjuvant therapy. Mol Clin Oncol (2014) 0.78
Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues. Oncotarget (2017) 0.77
Axillary lymph node clearance in patients with positive sentinel lymph node biopsy. Ann R Coll Surg Engl (2014) 0.77
The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer. Medicine (Baltimore) (2015) 0.77
Low-dose-area-constrained helical TomoTherapy-based whole breast radiotherapy and dosimetric comparison with tangential field-in-field IMRT. Biomed Res Int (2013) 0.77
Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells. J Nanosci Nanotechnol (2015) 0.76
Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas? Patholog Res Int (2010) 0.76
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature (2008) 6.16
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Cellulose biosynthesis and function in bacteria. Microbiol Rev (1991) 5.13
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA (1998) 5.09
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
The effect of bedside case presentations on patients' perceptions of their medical care. N Engl J Med (1997) 4.63
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
The relationship of physician medical interview style to patient satisfaction. J Fam Pract (1991) 4.38
Three cdg operons control cellular turnover of cyclic di-GMP in Acetobacter xylinum: genetic organization and occurrence of conserved domains in isoenzymes. J Bacteriol (1998) 3.81
Inferences on the association parameter in copula models for bivariate survival data. Biometrics (1995) 3.77
Genetic organization of the cellulose synthase operon in Acetobacter xylinum. Proc Natl Acad Sci U S A (1990) 3.74
PicoGreen quantitation of DNA: effective evaluation of samples pre- or post-PCR. Nucleic Acids Res (1996) 3.74
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 3.60
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys (1995) 3.32
Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer (1998) 3.32
The effects of two continuing medical education programs on communication skills of practicing primary care physicians. J Gen Intern Med (1993) 3.21
Tissue microarray: a new technology for amplification of tissue resources. Cancer J (2001) 3.19
Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. Mol Cell Biol (1998) 3.09
Relative risk trees for censored survival data. Biometrics (1992) 2.98
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
A database of vertebrate longevity records and their relation to other life-history traits. J Evol Biol (2009) 2.93
The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives. J Biol Chem (1990) 2.84
Exploitation of gene(s) involved in 2,4-diacetylphloroglucinol biosynthesis to confer a new biocontrol capability to a Pseudomonas strain. Appl Environ Microbiol (1992) 2.78
Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys (1998) 2.77
Legal regulation and quality control of medical practice under the British health service. N Engl J Med (1966) 2.76
ISOLATION OF INFLUENZA A BY INTRAALLANTOIC INOCULATION OF UNTREATED THROAT WASHINGS. Science (1943) 2.68
Occupational safety and health: unconstitutional searches. Am J Public Health (1977) 2.67
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst (1995) 2.64
Privacy, confidentiality and other legal considerations in the establishment of a centralized health-data system. N Engl J Med (1969) 2.61
Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 2.46
A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis (1998) 2.42
Genetic data indicate that proteins containing the GGDEF domain possess diguanylate cyclase activity. FEMS Microbiol Lett (2001) 2.39
Chronic conditions that lead to functional limitation in the elderly. J Gerontol (1994) 2.36
Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol (2001) 2.35
Sounding Board. The ethics of medical participation in capital punishment by intravenous drug injection. N Engl J Med (1980) 2.35
Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst (1989) 2.31
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Physicians' psychosocial beliefs correlate with their patient communication skills. J Gen Intern Med (1995) 2.20
Human immune response to sand fly salivary gland antigens: a useful epidemiological marker? Am J Trop Med Hyg (2000) 2.18
Massachusetts patients' Bill of Rights: cabbages, kings, sausages and laws. N Engl J Med (1979) 2.18
Phosphodiesterase A1, a regulator of cellulose synthesis in Acetobacter xylinum, is a heme-based sensor. Biochemistry (2001) 2.16
Governmental regulation of the use of human subjects in medical research; The approach of two federal agencies. Daedalus (1969) 2.14
Tumor chemosensitivity and chemoresistance assays. Cancer (1996) 2.14
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis (1988) 2.05
Clinicians are from Mars and pathologists are from Venus. Arch Pathol Lab Med (2000) 2.05
Doctors as managers. N Z Med J (2000) 2.03
Law-medicine notes. Pregnant schoolteachers--the right to bear children and the right to work. N Engl J Med (1974) 2.01
Public health and the law. The legal responsibility of a state university medical center. Am J Public Health Nations Health (1969) 2.01
Health problems of the poor: a legal advocacy program. Am J Public Health Nations Health (1970) 2.00
A profile of the health-promoting behaviors of physicians and lawyers. N Engl J Med (1980) 2.00
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys (1993) 1.99
Extraskeletal Ewing's sarcoma: results of combined modality treatment. J Clin Oncol (1983) 1.99
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res (2000) 1.97
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93
The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer (1984) 1.93
A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol (2003) 1.93
Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev (2003) 1.91
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol (1990) 1.87
Community mental health and the commitment laws: a radical new approach is needed. Am J Public Health Nations Health (1967) 1.86
Designs for experiments--parallel comparisons of treatment. N Engl J Med (1983) 1.85
Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med (1982) 1.83
Experimentation in children. A reexamination of legal ethical principles. JAMA (1969) 1.82
Asking questions about medication: analysis of physician-patient interactions and physician perceptions. Med Care (1999) 1.82
Studies without internal controls. N Engl J Med (1984) 1.81
Crossover and self-controlled designs in clinical research. N Engl J Med (1984) 1.81
The phosphoenolpyruvate-dependent carbohydrate: phosphotransferase system enzymes II as chemoreceptors in chemotaxis of Escherichia coli K 12. Mol Gen Genet (1981) 1.81
Public health and the law. Comprehensive health planning: audacious law-making. Am J Public Health Nations Health (1968) 1.78
Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York. Cancer Epidemiol Biomarkers Prev (1998) 1.77
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol (1994) 1.77
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Toward effective discussion of discipline and corporal punishment during primary care visits: findings from studies of doctor-patient interaction. Pediatrics (1994) 1.74
Public warnings of the risk in oral polio vaccine. Am J Public Health (1975) 1.72
Empirical Bayes methods for stabilizing incidence rates before mapping. Epidemiology (1994) 1.72
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst (1996) 1.70
Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg (1980) 1.69
Random effects models with non-parametric priors. Stat Med (1993) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys (1997) 1.65
Physician satisfaction with primary care office visits. Collaborative Study Group of the American Academy on Physician and Patient. Med Care (1993) 1.64
Synergistic sedation with propofol and midazolam in intensive care patients after coronary artery bypass grafting. Crit Care Med (1998) 1.63
Rights of privacy in medical practice. Lancet (1965) 1.63
A randomized controlled trial of quality assurance in sixteen ambulatory care practices. Med Care (1985) 1.62
[Health inequalities in Barcelona and Valencia]. Med Clin (Barc) (1993) 1.61
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol (2001) 1.61
Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum (1983) 1.60
Evidence for a cyclic diguanylic acid-dependent cellulose synthase in plants. Plant Cell (1991) 1.59
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys (1999) 1.58
Effects of antihypertensive therapy on serum lipids. Ann Intern Med (1995) 1.57
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol (1996) 1.57
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol (1996) 1.57